Array BioPharma Inc, binimetinib, Braftovi, encorafenib, Mektovi, Pfizer
Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation
The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to t..
Bosulif, Bosutinib, chronic myelogenous leukemia, CML, Pfizer
Bosutinib is approved by the FDA for pediatric patients with chronic myelogenous leukemia
Nov 2023: For paediatric patients aged one year and above with chronic phase (CP) Ph+ chronic myelogenous leukaemia (CML), either newly diagnosed (ND) or resistant or intolerant (R/I) to previous therapy, the Food and Drug Admini..
Pfizer, TALAPRO-2, Talazoparib
Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
ADVL0912, anaplastic lymphoma kinase, lymphoma, NCT00939770, Pfizer, Xalkori
Crizotinib is approved by FDA for ALK-positive inflammatory myofibroblastic tumor
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric patients 1 year of age and older who were diagnosed with unresectable, recurr..
ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Ventana Medical Systems
Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC.
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..
anaplastic lymphoma kinase, B7461006, CDx Assay, Food and Drug Administration, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Ventana Medical Systems
Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..
Bharat Biotech, Coronavirus, Covaxin, COVID, Covid Vaccine, Covishield, Pfizer
COVID-19 Vaccine – All that you wanted to know
Dr. Julie Gralow answers queries on COVID-19 vaccine.How can we be sure the vaccines are safe if they were produced and approved in such a short period of time?The medical community has been working to make COVID-19 vaccines avail..